Efficacy of infliximab in long-lasting refractory Kawasaki disease.
Zulian
F
F
Zanon
G
G
Martini
G
G
Mescoli
G
G
Milanesi
O
O
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002675:Child, Preschool; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D014859:Warfarin; D000069285:Infliximab; D001241:Aspirin